Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DBH | P09172 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981529 | 0.90 | CHRM2 (0.44) | HSP90AA1DBHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3981914 | 0.88 | HSP90AA1 (0.37) | HSP90AA1HSP90B1DBHWDR5 | |
| SCHEMBL3977716 | 0.87 | HSP90AA1 (0.42) | HSP90AA1HSP90B1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3986843 | 0.87 | HSP90AA1 (0.45) | HSP90AA1HSP90B1THRBCYP1A2CYP3A4 | |
| SCHEMBL3979802 | 0.87 | HSP90AA1 (0.51) | HSP90AA1HSP90B1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3980220 | 0.86 | HSP90AA1 (0.38) | HSP90AA1HSP90B1DBHWDR5 | |
| SCHEMBL3979725 | 0.84 | HSP90AA1 (0.39) | HSP90AA1HSP90B1MEN1KMT2AWDR5 | |
| SCHEMBL3979559 | 0.83 | HSP90AA1 (0.44) | HSP90AA1HSP90B1POLBDBHCYP1A2 | |
| SCHEMBL3985095 | 0.82 | CYP1A2 (0.50) | HSP90AA1HSP90B1POLBCYP1A2CYP2D6 | |
| SCHEMBL3986917 | 0.82 | HSP90AA1 (0.38) | HSP90AA1HSP90B1CYP1A2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | claimed |
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | claimed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| EP-1869012-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-26 | — | — | EP | disclosed |
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006107923-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | IL4I1, NFKBIA, BRD4 | HSP90AA1 675/4885HSP90B1 557/4885POLB 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.